Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Core Scientific (CORZ) over the last 5 years, with Q3 2025 value amounting to $453.4 million.

  • Core Scientific's Cash & Equivalents rose 7921.3% to $453.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $453.4 million, marking a year-over-year increase of 7921.3%. This contributed to the annual value of $836.2 million for FY2024, which is 155883.08% up from last year.
  • Core Scientific's Cash & Equivalents amounted to $453.4 million in Q3 2025, which was up 7921.3% from $581.3 million recorded in Q2 2025.
  • In the past 5 years, Core Scientific's Cash & Equivalents ranged from a high of $836.2 million in Q4 2024 and a low of $1.6 million during Q3 2021
  • Its 5-year average for Cash & Equivalents is $189.9 million, with a median of $96.1 million in 2024.
  • The largest annual percentage gain for Core Scientific's Cash & Equivalents in the last 5 years was 618628.99% (2022), contrasted with its biggest fall of 8652.43% (2022).
  • Core Scientific's Cash & Equivalents (Quarter) stood at $117.9 million in 2021, then tumbled by 86.52% to $15.9 million in 2022, then soared by 217.36% to $50.4 million in 2023, then soared by 1558.83% to $836.2 million in 2024, then tumbled by 45.77% to $453.4 million in 2025.
  • Its Cash & Equivalents stands at $453.4 million for Q3 2025, versus $581.3 million for Q2 2025 and $697.9 million for Q1 2025.